Back
Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders
Phase 1 data show that BGB-16673 is eliminated through intestinal and biliary excretion, limiting CYP3A-mediated interactions.
Investigating CYP3A-mediated Drug-Drug Interactions With BTK Degraders
Episodes
All
All
Please check back later for more content.
Advertisement
Advertisement
Trending on OncLive
1
INBRX-106 Plus Pembrolizumab Improves Responses and PFS in First-Line PD-L1–Positive HNSCC
2
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
3
Five Under 5: Top Oncology Videos for the Week of 9/27
4
AUA Releases Guideline Amendment for NMIBC
5